CooperSurgical Company Profile

Background

Overview

CooperSurgical, established in 1990, is a leading global medical device company specializing in women's health and fertility solutions. As a subsidiary of The Cooper Companies, Inc., headquartered in Trumbull, Connecticut, CooperSurgical has developed a comprehensive portfolio of over 600 medical devices and services aimed at enhancing women's healthcare.

Mission and Vision

CooperSurgical's mission is to accelerate solutions for life's most important moments, focusing on providing healthcare providers with innovative medical solutions that deliver rapid results and effective treatments. Their vision is a world of healthy women, babies, and families.

Industry Significance

With a global presence in over 100 countries and a workforce of approximately 3,000 employees, CooperSurgical plays a pivotal role in advancing women's health through its diverse product offerings, including reproductive care, fertility, birth, and general gynecological care.

Key Strategic Focus

Core Objectives

CooperSurgical aims to provide healthcare providers with a comprehensive range of innovative medical solutions, enabling them to deliver rapid results and effective treatments to women, babies, and families.

Areas of Specialization

Fertility Solutions: Offering advanced assisted reproductive technology (ART) and genomic solutions to enhance the work of ART professionals.

Women's Health: Providing a wide array of medical devices and services for obstetricians and gynecologists, including diagnostic and surgical instruments.

Key Technologies Utilized

CooperSurgical employs state-of-the-art technologies in its product offerings, such as single-use cordless surgical retractors with integrated multi-LED light sources and dual smoke evacuation channels, as well as single-use surgical suction devices with integrated cordless radial LED light sources.

Primary Markets Targeted

The company primarily serves healthcare providers, including obstetricians, gynecologists, fertility clinics, and hospitals, equipping them with tools needed to manage women's reproductive health, fertility, and pregnancy effectively.

Financials and Funding

Funding History

CooperSurgical has grown through organic development and strategic acquisitions, including the purchase of obp Surgical in August 2024 for approximately $100 million, which expanded its portfolio of leading medical devices.

Recent Funding Rounds

The acquisition of obp Surgical in August 2024 was a significant investment, enhancing CooperSurgical's surgical device offerings.

Notable Investors

As a subsidiary of The Cooper Companies, Inc., CooperSurgical benefits from the financial backing and resources of its parent company, which reported total revenue of $3.9 billion in fiscal year 2024.

Utilization of Capital

The capital from recent acquisitions has been utilized to expand CooperSurgical's product portfolio, particularly in the surgical device segment, thereby enhancing its market position in women's health and fertility solutions.

Pipeline Development

Key Pipeline Candidates

CooperSurgical's pipeline includes innovative surgical devices such as the ONETRAC™ portfolio of surgical retractors and suction devices, which complement existing products like INSORB®, Lone Star®, and the Doppler Blood Flow Monitor.

Stages of Development

The ONETRAC™ products have been integrated into CooperSurgical's portfolio following the acquisition of obp Surgical in August 2024.

Target Conditions

These surgical devices are designed to enhance surgical procedures by providing improved illumination and smoke evacuation, thereby improving safety and efficiency in the operating room.

Anticipated Milestones

The integration of ONETRAC™ products is expected to strengthen CooperSurgical's surgical device offerings and contribute to revenue growth in the surgical segment.

Technological Platform and Innovation

Proprietary Technologies

ONETRAC™ Surgical Devices: A suite of single-use cordless surgical retractors and suction devices with integrated multi-LED light sources and dual smoke evacuation channels.

Significant Scientific Methods

Assays and Diagnostic Tools: CooperSurgical offers a range of diagnostic tools and assays to support women's health, including products for in vitro fertilization (IVF) and other reproductive health services.

Leadership Team

Key Executives

Albert G. White III: President & Chief Executive Officer of CooperSurgical.

Holly Sheffield: President of CooperSurgical.

Mark Valentine: Chief Commercial Officer.

Kim Shaffer: Vice President & Assistant General Counsel.

Kristofer Karlsson: Executive Vice President, Global Fertility Solutions.

Professional Backgrounds and Contributions

Albert G. White III: Served as Chief Financial Officer and Executive Vice President before becoming CEO in May 2018. He has been instrumental in leading CooperSurgical's strategic initiatives and growth.

Holly Sheffield: As President of CooperSurgical, she oversees the company's operations and strategic direction, focusing on advancing women's healthcare.

Competitor Profile

Market Insights and Dynamics

The women's health and fertility solutions market is highly competitive, with numerous established players vying for market share. CooperSurgical competes with companies such as Vitrolife, Fujifilm Irvine Scientific, and Hologic, Inc., which offer similar products and services in the women's health sector.

Competitor Analysis

Vitrolife: A leading provider of IVF equipment and consumables, competing with CooperSurgical in lab solutions.

Fujifilm Irvine Scientific: Offers a range of products in the healthcare equipment space, including solutions for reproductive medicine.

Hologic, Inc.: Known for its advanced uterine health solutions, including hysteroscopes and other gynecological devices.

Strategic Collaborations and Partnerships

CooperSurgical has expanded its product portfolio through strategic acquisitions, such as the purchase of obp Surgical in August 2024, enhancing its surgical device offerings.

Operational Insights

CooperSurgical's extensive global presence, with direct distribution in 24 countries and a network of distributors, enables it to effectively compete in the women's health and fertility solutions market.

Strategic Opportunities and Future Directions

CooperSurgical continues to focus on innovation and strategic acquisitions to expand its product offerings and strengthen its position in the women's health and fertility solutions market. The integration of new technologies and products is expected to drive growth and enhance the company's competitive edge.